Effect of Xiaoke Wan and Xuezhikang on Mannan Binding Lectin in Patients with Type2 Diabetes Mellitus and Hyperlipidemia

ZHANG Yu-quan; YANG Jian-feng

doi:10.11653/syfj2013080274

您当前的位置：

首页 >

文章列表页 >

Effect of Xiaoke Wan and Xuezhikang on Mannan Binding Lectin in Patients with Type2 Diabetes Mellitus and Hyperlipidemia

更新时间：2024-01-04

- Effect of Xiaoke Wan and Xuezhikang on Mannan Binding Lectin in Patients with Type2 Diabetes Mellitus and Hyperlipidemia
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 19, Issue 8, Pages: 274-277(2013)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.11653/syfj2013080274
  CLC：
- Published：2013
- 稿件说明：
移动端阅览
ZHANG Yu-quan, YANG Jian-feng. Effect of Xiaoke Wan and Xuezhikang on Mannan Binding Lectin in Patients with Type2 Diabetes Mellitus and Hyperlipidemia[J]. Chinese journal of experimental traditional medical formulae, 2013, 19(8): 274-277.
DOI：

ZHANG Yu-quan, YANG Jian-feng. Effect of Xiaoke Wan and Xuezhikang on Mannan Binding Lectin in Patients with Type2 Diabetes Mellitus and Hyperlipidemia[J]. Chinese journal of experimental traditional medical formulae, 2013, 19(8): 274-277. DOI： 10.11653/syfj2013080274.

摘要

目的: 探讨消渴丸联合血脂康对2型糖尿病高脂血症甘露聚糖结合凝集素mannan binding lectin(MBL)的影响。方法: 80例2型糖尿病高脂血症患者随机分为观察组和对照组各40例。观察组予以消渴丸

开始10丸/次

早餐及午餐前各1次;血脂康胶囊

2粒/次

口服

2次/d。对照组予以格列本脲片

开始2.5 mg

早餐及午餐前各1次;辛伐他汀

20 mg/次

1次/d。两组均每周根据血糖水平调整消渴丸和格列本脲用量。疗程均为12周。另设健康对照组20例。测量治疗前后空腹血糖(FBG)

餐后2 h血糖(2 hPG)

糖化血红蛋白(HbAlc)及总胆固醇(TC)

甘油三酯(TG)

低密度脂蛋白胆固醇(LDL-C)

高密度脂蛋白(HDL-C)

并检测MBL。结果: 治疗后两组FBG

2 hPG均较治疗前明显降低

组间比较差异不明显;治疗后两组HbA1c均较治疗前明显降低

观察组HbA1c下降更明显(P<0.05);治疗后观察组血脂水平与正常对照组比较差异不明显

对照组LDL-C水平仍高于健康对照组(P<0.05);治疗后观察组MBL为(0.71±0.25)mg·L-1

仍低于健康对照组(P<0.05)

但较治疗前明显上升(P<0.01);对照组MBL为(0.40±0.21)mg·L-1

与治疗前相比呈下降趋势。结论: 消渴丸联合血脂康对2型糖尿病高脂血症的血糖及血脂均能有效控制

并能上调MBL水平

有利于炎症的控制。

Abstract

Objective: To investigate the effect of Xiaoke Wan and Xuezhikang on mannan binding lectin (MBL) in patients with type2 diabetes mellitus and hyperlipidemia. Method: Eighty patients with type2 diabetes mellitus combined with hyperlipidemia were randomly divided into observation group and control group (n=40 each). Observation group was firstly received Xiaoke Wan

10 pills

before breakfast and lunch. Patients in observation group were also orally received Xuezhikang capsules

2 capsules

bid. Control group was firstly received glibenclamide tablet

2.5 mg before breakfast and lunch. Patients in control group were also orally received simvastatin

20 mg daily. The amount of Xiaoke Wan and glibenclamide were adjusted according to blood glucose level in the two groups. The treatment course of the two groups lasted 12 weeks. Additional 20 normal persons were grouped as the healthy control group. Fasting blood glucose (FBG)

level of postprandial 2 h blood glucose (2 hPG)

glycated hemoglobin (HbAlc)

total cholesterol (TC)

triglyceride (TG)

low density lipoprotein chotesterol(LDL-C) and high density lipoprotein chotesterol(HDL-C) and MBL were tested before and after treatment. Result: After treatment

FBG and 2 h PBG in the two groups were significantly lower than those before treatment

but there was no significant difference between the two groups. After treatment

HbA1c in the two groups was decreased significantly

and that in observation group decreased more (P<0.05). After treatment

there was no significant difference in blood glucose level between the two groups

LDL-C in control group was still higher than normal control group (P<0.05). After treatment

MBL in observation group was (0.71±0.25) mg·L-1

which was lower than that in normal control group (P<0.05)

but significantly higher than that before treatment (P<0.01). MBL in control group was (0.40±0.21) mg·L-1

which was lower than that before treatment. Conclusion: Xiaoke Wan combined with Xuezhikang can effectively control blood glucose and lipids in the patients with type2 diabetes mellitus and hyperlipidemia

raise MBL level

and help to control inflammation.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical Trial of Xuezhikang Capsule for Treating Hyperlipidemia

Clinical Efficacy of Zhuyuwan in Treatment of Hyperlipidemia with Syndrome of Phlegm Turbidity and Obstruction

Zhuyuwan in Treatment of Hyperlipidemia Complicated with Carotid Atherosclerosis： A Randomized Controlled Trial

Mechanism of Wendantang in Intervention of ApoE^-/- Hyperlipidemic Mice Based on Liver Metabolomics

Polygonati Odorati Rhizoma Polysaccharides Ameliorate Hyperlipidemia in Mice by Regulating Gut Microbiota

Related Author

Wang Junxian1

Su Mei zhe1

Lu Zongliang2

Kou Wenrong2

ChiJadn3

Yu Pulin3

Wang Wenhua4

YANG Lele

Related Institution

Chengdu University of TCM

Hospital of Chengdu University of Traditional Chinese Medicine （TCM）

Hospital of Chengdu University of TCM

Chengdu University of Traditional Chinese Medicine（TCM）

Research Center for Differentiation and Development of Traditional Chinese Medicine （TCM） Basic Theory/Jiangxi Province Key Laboratory of Biological Etiologies of TCM/First-Level Discipline Platform of Chinese and Western Integrative Medicine/Experimental Animal and Scientific Technology Center of Jiangxi University of Chinese Medicine/School of Pharmacy， Jiangxi University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰